Mayelana-umdlavuza / ukwelashwa / izidakamizwa / isisu

Izidakamizwa zivunyelwe i-Esophageal Cancer

Leli khasi libala imishanguzo yomdlavuza evunyelwe yiFood and Drug Administration (FDA) yomdlavuza wokuqopha, kufaka phakathi umdlavuza we-gastroesophageal junction. Uhlu lufaka amagama ejwayelekile namagama ezimpawu. Amagama ezidakamizwa axhumanisa nezifinyezo ze-Cancer Information Information ze-NCI. Kungahle kube nezidakamizwa ezisetshenziswa kumdlavuza we-esophageal ezingekho ohlwini lapha.

Izidakamizwa zivunyelwe i-Esophageal Cancer

I-Keytruda (Pembrolizumab)

I-Pembrolizumab

Izinhlanganisela Zezidakamizwa Ezisetshenziswa Emdlavuzeni Wokuqothuka

I-FU-LV

XELIRI

Izidakamizwa zivunyelwe i-Gastroesophageal Junction Cancer

ICyramza (iRamucirumab)

I-Docetaxel

I-Herceptin (Trastuzumab)

I-Keytruda (Pembrolizumab)

I-Lonsurf (Trifluridine ne-Tipiracil Hydrochloride)

I-Pembrolizumab

URamucirumab

I-Taxotere (Docetaxel)

I-Trastuzumab

I-Trifluridine ne-Tipiracil Hydrochloride